| |
| | Business Wire: CyThera and Arcos in Binding Agreement to Merge. @ HighBeam Research (Site not responding. Last check: 2007-11-06) |
 | | CyThera, Inc. and Arcos BioScience, Inc., both privately held biotechnology companies focused on development of cell replacement therapies for the treatment of human degenerative diseases, announced they have signed a binding letter of intent to merge. |
 | | "CyThera and Arcos have collaborated closely for over two years on research that led to, among other things, the creation of nine human embryonic stem cell derivations," said Lutz B. Giebel, Ph.D., CyThera's chief executive officer. |
 | | Using technology pioneered by Jeanne Loring, Ph.D., chief scientific officer of Arcos BioScience, Arcos and CyThera scientists produced the cells during the Arcos collaboration with CyThera. |
| www.highbeam.com /library/doc0.asp?DOCID=1G1:84641153&refid=ip_encyclopedia_hf (312 words) |
|